Prism Medico and Pharmacy Ltd (512217)
Latest quarterly results (Q4 FY26)
In its latest reported quarter, Q4 FY26, Prism Medico's net interest income was ₹0.3 Cr (+300.0% year on year, +300.0% on the previous quarter), and net profit ₹-0.2 Cr (against a profit a year earlier).
| Q4 FY26 (₹ Cr) | Value | YoY vs Q4 FY25 | QoQ |
|---|---|---|---|
| Net interest income | ₹0.3 | +300.0% | +300.0% |
| Net profit | ₹-0.2 | to loss | loss widened |
| EPS (₹) | -0.40 | to loss | loss widened |
📢 Recent Corporate Announcements
Prism Medico and Pharmacy Ltd has submitted a compliance filing under Regulation 57(4) of SEBI LODR Regulations. The company confirmed that it has no non-convertible securities issued for which interest, dividend, or principal is payable during the upcoming quarter from October 1, 2026, to December 31, 2026. This is a standard quarterly compliance filing confirming zero scheduled debt servicing obligations on listed debt instruments.
- Regulation 57(4) intimation filed for the quarter beginning October 1, 2026, and ending December 31, 2026
- Company confirmed zero non-convertible securities with interest, dividend, or principal due
- Scrip code 512217 / SYMBOL: PRISMMEDI submitted to BSE and MSEI on September 30, 2026
Prism Medico and Pharmacy has issued its 24th AGM notice proposing a major variation in the utilisation of its ₹25.00 Cr preferential issue proceeds. The company plans to cancel its original ₹23.00 Cr manufacturing capex (₹15.69 Cr for plant & machinery and ₹7.31 Cr for civil work) and reallocate the entire ₹23.00 Cr to acquire 2,30,00,000 equity shares in related-party entity Infuze Well Private Limited (IWPL). The proposed ₹23.00 Cr transaction exceeds the company's total market capitalisation of ₹18 Cr and represents a significant capital reallocation to a related party.
- Proposes reallocating ₹23.00 Cr of issue proceeds from manufacturing capex to subscribe to equity shares of related party Infuze Well Pvt Ltd.
- Discontinues original capex plans of ₹15.69 Cr for plant & machinery and ₹7.31 Cr for civil structures.
- Prefunded preferential issue comprised 75,00,000 equity shares and 50,00,000 convertible warrants totalling ₹25.00 Cr.
- Plans to acquire 2,30,00,000 equity shares of IWPL at ₹10 per share to make it a subsidiary.
- Shareholder voting scheduled at the 24th AGM on September 19, 2026.
Prism Medico and Pharmacy Ltd has scheduled its 24th Annual General Meeting (AGM) for Saturday, September 19, 2026, at 12:30 PM via Video Conferencing/OAVM. The company's Register of Members and Share Transfer Books will remain closed from September 13, 2026, to September 19, 2026 (both days inclusive). The cut-off date for remote e-voting eligibility is set for September 12, 2026. Remote e-voting commences on September 16, 2026, at 9:00 AM and concludes on September 18, 2026, at 5:00 PM.
- 24th AGM scheduled for September 19, 2026, at 12:30 PM via VC/OAVM
- Book closure period defined from September 13, 2026, to September 19, 2026
- Record/cut-off date for e-voting fixed as September 12, 2026
- Remote e-voting window open from September 16, 2026 (9:00 AM) to September 18, 2026 (5:00 PM)
Prism Medico and Pharmacy has issued its 24th AGM notice seeking shareholder approval to modify the objects of its ₹25.00 crore preferential issue (75 lakh shares and 50 lakh convertible warrants). The company has discontinued its original manufacturing capex plans of ₹15.69 crore for plant & machinery and ₹7.31 crore for civil works. Instead, it proposes to allocate ₹23.00 crore towards a strategic investment in freshly issued shares of related party Infuze Well Private Limited (IWPL) to make it a subsidiary.
- Discontinued ₹23.00 crore original capex allocated for manufacturing plant, machinery (₹15.69 Cr), and civil structures (₹7.31 Cr).
- Reallocated ₹23.00 crore towards acquiring equity shares in related party Infuze Well Private Limited (IWPL) to make it a subsidiary.
- Total preferential issue size stands at ₹25.00 crore, consisting of 75,00,000 equity shares and 50,00,000 convertible warrants allotted on May 05, 2026.
- ₹1.00 crore has been utilized till date towards purchase of land and building in District Sirmaur, Himachal Pradesh.
- 24th AGM scheduled for September 19, 2026 via video conferencing to seek shareholder approval.
Prism Medico and Pharmacy Ltd has proposed to vary the objects of its ₹25.00 Cr preferential issue (75,00,000 equity shares and 50,00,000 convertible warrants). The company is discontinuing previously planned capex of ₹15.69 Cr for medicine manufacturing machinery and ₹7.31 Cr for civil structures. Instead, ₹23.00 Cr will be redirected as a strategic investment to acquire freshly issued shares in related party Infuze Well Private Limited (IWPL) to make it a subsidiary, subject to shareholder approval at the AGM on September 19, 2026.
- Diverting ₹23.00 Cr of preferential issue proceeds to acquire shares in related party Infuze Well Pvt Ltd
- Discontinued ₹15.69 Cr allocation for plant and machinery and ₹7.31 Cr for civil structures
- Preferential issue comprises 75,00,000 equity shares and 50,00,000 convertible warrants totaling ₹25.00 Cr
- Deployment of ₹23.00 Cr is contingent upon receipt of balance warrant exercise consideration
- 24th AGM scheduled for September 19, 2026 via video conferencing to seek special resolution approval
Prism Medico has issued an AGM notice seeking shareholder approval to modify the objects of its ₹25.00 crore preferential issue. The company is discontinuing its planned ₹23.00 crore direct capex (machinery and civil works) to instead invest ₹23.00 crore into freshly issued equity shares of related-party entity Infuze Well Private Limited (IWPL) to make it a subsidiary. Whole-Time Director Sakshi Laller holds a 19.40% stake in IWPL. Additionally, the company is seeking approval for up to ₹70.00 crore of related-party transactions in FY27 against FY26 revenue of just ₹2.47 crore.
- Diverting ₹23.00 crore from originally planned manufacturing capex into acquiring related-party Infuze Well Private Limited.
- Original capex objects of ₹15.69 crore for plant/machinery and ₹7.31 crore for civil works discontinued entirely.
- Proposed investment of ₹23.00 crore exceeds the company's entire market capitalization of ~₹18 crore.
- Seeking shareholder approval for up to ₹70.00 crore in related-party purchase/sale transactions for FY27.
- 24th AGM scheduled for September 19, 2026, via Video Conferencing.
Prism Medico and Pharmacy Ltd announced the outcome of its board meeting held on August 24, 2026. The board approved the notice for its 24th Annual General Meeting scheduled for September 19, 2026, and set September 12, 2026, as the e-voting cut-off date. Additionally, the board recommended a variation in the objects and fund utilisation of the preferential issue previously approved on March 20, 2026, alongside corporate approvals under Section 186 for investing company funds.
- 24th AGM scheduled for September 19, 2026 at 12:30 PM via Video Conferencing.
- Cut-off date for electronic voting fixed as September 12, 2026; book closure from September 13 to September 19, 2026.
- Recommended variation in the objects and utilisation of proceeds from the preferential issue approved in the March 20, 2026 EGM.
- Appointed SDK & Associates as Secretarial Auditors for 5 financial years (FY 2026-27 to FY 2030-31).
Prism Medico and Pharmacy Ltd has scheduled a Board of Directors meeting on Monday, August 24, 2026. The board will consider and approve the Directors' Report for the financial year ended March 31, 2026, and fix the date and details for the 24th Annual General Meeting (AGM). Additionally, the board will deliberate on the re-appointment of statutory auditors M/s. Garg Mendiratta and Associates and the appointment of secretarial auditors M/s. SDK & Associates for a 5-year tenure (FY 2026-27 to FY 2030-31).
- Board meeting scheduled for August 24, 2026 at 01:00 P.M.
- Board to consider and approve Directors' Report for FY ended March 31, 2026
- Fixing date and book closure for the 24th Annual General Meeting
- Recommendation for re-appointment of Statutory Auditors M/s. Garg Mendiratta and Associates
- Proposed appointment of Secretarial Auditors M/s. SDK & Associates for 5 financial years (FY 2026-27 to FY 2030-31)
Prism Medico and Pharmacy Ltd reported a significant downturn in Q1 FY27, with revenue from operations falling to zero from Rs 158.87 Lakhs in the same quarter last year. The company posted a net loss of Rs 5.83 Lakhs, as other income of Rs 9.06 Lakhs failed to cover total expenses of Rs 14.89 Lakhs. Notably, the paid-up equity share capital more than doubled to Rs 13.56 Cr from Rs 6.06 Cr in the previous quarter, indicating a major capital infusion or corporate action not fully detailed in the results.
- Revenue from operations dropped to Rs 0.00 in Q1 FY27 compared to Rs 158.87 Lakhs in Q1 FY26.
- Net Loss of Rs 5.83 Lakhs recorded for the quarter ended June 30, 2026.
- Paid-up equity share capital increased by 123% to Rs 1,356.34 Lakhs from Rs 606.34 Lakhs.
- Other expenses of Rs 13.02 Lakhs constituted the bulk of the quarter's costs.
- Total comprehensive income swung from a profit of Rs 65.73 Lakhs YoY to a loss of Rs 5.83 Lakhs.
Prism Medico and Pharmacy Ltd has scheduled a board meeting for August 12, 2026, to approve its unaudited standalone financial results for the quarter ended June 30, 2026. This is a routine regulatory filing for the micro-cap NBFC, which currently has a market capitalization of approximately ₹18 Cr. The company reported a TTM revenue of ₹42 Cr but remains loss-making with a TTM PAT of ₹-1 Cr. Investors should note the recent increase in promoter holding from 25% to 30.2% as of May 2026.
- Board meeting scheduled for August 12, 2026, at 01:30 P.M.
- Agenda includes approval of unaudited standalone financial results for the quarter ended June 30, 2026.
- Meeting to be held at the registered office in Kala Amb, Himachal Pradesh.
- Promoter holding recently increased to 30.2% as of May 2026 from 25.5% in March 2026.
Prism Medico and Pharmacy Ltd has announced that its official website is now updated and functional in compliance with Regulation 46 of SEBI (LODR) Regulations, 2015. This is a procedural regulatory requirement for listed companies to ensure transparency and provide a portal for investor disclosures. The company is a micro-cap NBFC with a market capitalization of Rs 16 Cr and TTM revenue of Rs 42 Cr. This filing is administrative in nature and does not impact the company's financial performance or business operations.
- Website confirmed as functional at https://www.prismmedico.in as of July 30, 2026
- Compliance achieved under Regulation 46 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
- Company maintains a small market capitalization of Rs 16 Cr
- Promoter holding recently increased to 30.2% in May 2026 from 25.5% in March 2026
Financial Performance
Financial analysis data not yet available for this company.
Operational Drivers
Operational analysis data not yet available for this company.
Strategic Growth
Strategic growth analysis not yet available for this company.
External Factors
External factors analysis not yet available for this company.
Regulatory & Governance
Regulatory analysis not yet available for this company.
Risk Analysis
Risk analysis not yet available for this company.
